AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
THOUSAND OAKS, Calif., May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, and other members of the Amgen team will participate. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
加利福尼亞州千橡市，2024年5月15日 /PRNewswire/ — 在TEZSPIRE公佈新數據後，安進（納斯達克股票代碼：AMGN）將於太平洋時間2024年5月20日星期一下午1點爲投資界舉辦網絡直播電話會議 在2024年5月19日和20日的美國胸科學會（ATS）國際會議上，研究慢性阻塞性肺病（COPD）。該演講還將概述安進創新炎症產品組合中的其他項目。安進研發執行副總裁兼首席科學官傑伊·布拉德納以及安進團隊的其他成員將參加。網絡直播將同時通過互聯網播出，並將向新聞媒體成員、投資者和公衆開放。
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
該網絡直播與管理層在某些投資者和醫學會議上發表的有關安進業務發展的其他精選演講一樣，可以在安進網站的 “投資者” 下找到。有關演示時間、網絡直播可用性和網絡直播鏈接的信息，請參見安進的投資者關係活動日曆。網絡直播將在活動結束後至少 90 天內存檔並可供重播。
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
關於安進
安進發現、開發、製造和交付創新藥物，以幫助數百萬患者對抗世界上一些最棘手的疾病。40多年前，安進幫助建立了生物技術行業，並一直處於創新的前沿，利用技術和人類遺傳數據來超越當今的已知水平。安進正在推進廣泛而深入的產品線，該產品線建立在其現有藥物組合的基礎上，用於治療癌症、心臟病、骨質疏鬆症、炎症性疾病和罕見疾病。
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average, and it is also part of the Nasdaq-100 Index, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
2024年，安進被Fast Company評爲 “全球最具創新力的公司” 之一，被《福布斯》評爲 “美國最佳大型僱主” 之一，以及其他外部認可。安進是構成道瓊斯工業平均指數的30家公司之一，它也是納斯達克100指數的一部分，其中包括按市值在納斯達克股票市場上市的最大、最具創新性的非金融公司。
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, TikTok, YouTube and Threads.
欲了解更多信息，請訪問 Amgen.com 並在 X、LinkedIn、Instagram、抖音、YouTube 和 Threads 上關注安進。
CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)
聯繫人：安進、千橡市
Elissa Snook，609-251-1407（媒體）
賈斯汀·克萊斯，805-313-9775（投資者）
SOURCE Amgen
來源 Amgen
譯文內容由第三人軟體翻譯。